European guidelines on managing adverse effects of medication for ADHD.
The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical subspecialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks.
Child and Adolescent Psychiatry, The Centre for Child Health, Dundee, UK. JGraham3@nhs.net
J
J
Graham
T
T
Banaschewski
J
J
Buitelaar
D
D
Coghill
M
M
Danckaerts
R W
RW
Dittmann
M
M
Döpfner
R
R
Hamilton
C
C
Hollis
M
M
Holtmann
M
M
Hulpke-Wette
M
M
Lecendreux
E
E
Rosenthal
A
A
Rothenberger
P
P
Santosh
J
J
Sergeant
E
E
Simonoff
E
E
Sonuga-Barke
I C K
IC
Wong
A
A
Zuddas
H-C
HC
Steinhausen
E
E
Taylor
D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000523:psychology; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000401:mortality / Q000517:prevention & control*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D054796:Drug Dosage Calculations; D004361:Drug Tolerance; D017723:Drug Utilization Review; D005060:Europe; D006801:Humans; D008991:Monitoring, Physiologic / Q000379:methods / Q000592:standards; D011437:Propylamines / Q000008:administration & dosage / Q000009:adverse effects*; D018570:Risk Assessment; D019966:Substance-Related Disorders / Q000209:etiology / Q000517:prevention & control; D013406:Suicide, Attempted / Q000517:prevention & control* / Q000523:psychology
D018759:Adrenergic Uptake Inhibitors; D000697:Central Nervous System Stimulants; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride